142 related articles for article (PubMed ID: 36758196)
1. Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors.
King JM; Cheng M; Kesler K; Ashkar R; Althouse SK; Hanna NH; Einhorn LH; Adra N
J Clin Oncol; 2023 Aug; 41(23):3939-3944. PubMed ID: 36758196
[TBL] [Abstract][Full Text] [Related]
2. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor.
Venishetty N; Taylor J; Xi Y; Howard JM; Ng YS; Wong D; Woldu SL; De Leon AD; Pedrosa I; Margulis V; Bagrodia A
Clin Genitourin Cancer; 2024 Feb; 22(1):33-37. PubMed ID: 37468341
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor.
Ghodoussipour S; Daneshmand S
Urol Clin North Am; 2019 Aug; 46(3):389-398. PubMed ID: 31277733
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
5. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
6. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
7. Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors.
King J; Ashkar R; Kesler K; Althouse SK; Hanna NH; Einhorn LH; Adra N
JAMA Oncol; 2024 Jan; 10(1):132-134. PubMed ID: 37943568
[TBL] [Abstract][Full Text] [Related]
8. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
9. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors.
Calaway AC; Kern SQ; Crook D; Tong Y; Masterson TA; Adra N; Einhorn LH; Foster RS; Cary C
J Urol; 2021 Dec; 206(6):1430-1437. PubMed ID: 34288715
[TBL] [Abstract][Full Text] [Related]
10. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
Besse B; Grunenwald D; Fléchon A; Caty A; Chevreau C; Culine S; Théodore C; Fizazi K
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):448-52. PubMed ID: 19185168
[TBL] [Abstract][Full Text] [Related]
11. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
[TBL] [Abstract][Full Text] [Related]
12. Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group.
Gerdtsson A; Thor A; Grenabo Bergdahl A; Almås B; Håkansson U; Törnblom M; Negaard HFS; Glimelius I; Halvorsen D; Karlsdóttir Á; Sagstuen Haugnes H; Engen Andreassen K; Melsen Larsen S; Holmberg G; Wahlqvist R; Tandstad T; Cohn-Cedermark G; Ståhl O; Kjellman A
Eur Urol Oncol; 2022 Apr; 5(2):235-243. PubMed ID: 33750683
[TBL] [Abstract][Full Text] [Related]
13. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
Herr HW; Toner GC; Geller NL; Bosl GJ
Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
[TBL] [Abstract][Full Text] [Related]
14. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
15. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
16. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach.
Sonneveld DJ; Sleijfer DT; Koops HS; Keemers-Gels ME; Molenaar WM; Hoekstra HJ
Cancer; 1998 Apr; 82(7):1343-51. PubMed ID: 9529027
[TBL] [Abstract][Full Text] [Related]
17. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.
Gupta A; Feifer AH; Gotto GT; Kraus D; Motzer R; Bosl GJ; Bajorin D; Feldman DR; Carver B; Sheinfeld J
Urology; 2011 Mar; 77(3):655-9. PubMed ID: 21377010
[TBL] [Abstract][Full Text] [Related]
19. Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.
Pietzak EJ; Assel M; Becerra MF; Tennenbaum D; Feldman DR; Bajorin DF; Motzer RJ; Bosl GJ; Carver BS; Sjoberg DD; Sheinfeld J
Urology; 2018 Aug; 118():114-118. PubMed ID: 29704586
[TBL] [Abstract][Full Text] [Related]
20. Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.
Inci K; Dogan HS; Akdogan B; Baydar DE; Ergen A; Ozen H
Urol Oncol; 2011; 29(1):38-42. PubMed ID: 19269199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
